CA2306877A1 - Compositions d'insuline insolubles - Google Patents
Compositions d'insuline insolubles Download PDFInfo
- Publication number
- CA2306877A1 CA2306877A1 CA002306877A CA2306877A CA2306877A1 CA 2306877 A1 CA2306877 A1 CA 2306877A1 CA 002306877 A CA002306877 A CA 002306877A CA 2306877 A CA2306877 A CA 2306877A CA 2306877 A1 CA2306877 A1 CA 2306877A1
- Authority
- CA
- Canada
- Prior art keywords
- acylated
- insulin
- fatty acid
- human insulin
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des compositions insolubles contenant des protéines acylées, choisies dans le groupe constitué par l'insuline acylée, un analogue de l'insuline acylée, et la pro-insuline acylée; elle concerne également des formulations de ces compositions, conçues pour un apport parentéral ou d'autres moyens d'apport à un patient, aux fins d'une régulation accrue des taux de glycémie. L'invention concerne notamment des compositions comprenant une protéine acylée complexée avec du zinc, une protamine et un composé phénolique, de façon que le microcristal résultant soit analogue à la forme cristalline de l'insuline semilente Hagedorn (NPH). De manière étonnante, on a découvert que des compositions de telles protéines acylées possèdent des pharmacocinétiques de libération sous-cutanée supérieures sur le plan thérapeutique, ainsi que des glucodynamiques à profil plus étendu et plus plat, que celles de préparations d'insuline NPH, actuellement disponibles sur le marché. Par ailleurs, les cristaux de l'invention conservent certaines propriétés avantageuses des cristaux de NPH, en ce qu'ils peuvent être facilement remis en suspension et peuvent également être mélangés à des insulines solubles.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6310497P | 1997-10-24 | 1997-10-24 | |
US60/063,104 | 1997-10-24 | ||
US8893098P | 1998-06-11 | 1998-06-11 | |
US60/088,930 | 1998-06-11 | ||
PCT/US1998/022434 WO1999021578A1 (fr) | 1997-10-24 | 1998-10-22 | Compositions d'insuline insolubles |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2306877A1 true CA2306877A1 (fr) | 1999-05-06 |
Family
ID=26743043
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002306905A Abandoned CA2306905A1 (fr) | 1997-10-24 | 1998-10-22 | Analogues d'insuline acylee par un acide gras |
CA002306877A Abandoned CA2306877A1 (fr) | 1997-10-24 | 1998-10-22 | Compositions d'insuline insolubles |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002306905A Abandoned CA2306905A1 (fr) | 1997-10-24 | 1998-10-22 | Analogues d'insuline acylee par un acide gras |
Country Status (21)
Country | Link |
---|---|
US (3) | US6268335B1 (fr) |
EP (1) | EP1039920A4 (fr) |
JP (2) | JP2001521006A (fr) |
KR (1) | KR20010024556A (fr) |
CN (1) | CN1276731A (fr) |
AR (1) | AR020047A1 (fr) |
AU (2) | AU1111799A (fr) |
BR (1) | BR9813111A (fr) |
CA (2) | CA2306905A1 (fr) |
CO (1) | CO4970769A1 (fr) |
EA (1) | EA200000453A1 (fr) |
HR (1) | HRP20000236A2 (fr) |
HU (1) | HUP0004169A3 (fr) |
ID (1) | ID24890A (fr) |
IL (1) | IL134901A0 (fr) |
NO (1) | NO20002038L (fr) |
PE (1) | PE123799A1 (fr) |
PL (1) | PL340255A1 (fr) |
SV (1) | SV1998000125A (fr) |
TR (1) | TR200001050T2 (fr) |
WO (2) | WO1999021573A1 (fr) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
US6531448B1 (en) * | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
US20030054015A1 (en) * | 2000-12-25 | 2003-03-20 | Shinichiro Haze | Sympathetic-activating perfume composition |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US20020155614A1 (en) * | 2001-02-21 | 2002-10-24 | Tomlinson Andrew J. | Peptide esterification |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
CA2452044A1 (fr) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-melanges de polypeptide glp-1 et d'insuline basale |
US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
DE60217367T2 (de) * | 2001-09-19 | 2007-10-18 | Elan Pharma International Ltd. | Nanopartikelzusammensetzungen enthaltend insulin |
AU2002346491A1 (en) * | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
KR20040070237A (ko) * | 2001-12-20 | 2004-08-06 | 일라이 릴리 앤드 캄파니 | 연장된 작용 시간을 갖는 인슐린 분자 |
US20040038864A1 (en) * | 2002-06-27 | 2004-02-26 | Per Balschmidt | Use of dimethyl sulfone as isotonicity agent |
JP2006519791A (ja) * | 2003-03-13 | 2006-08-31 | ノボ ノルディスク アクティーゼルスカブ | 新規なnphインスリン製剤 |
US20060258561A1 (en) * | 2003-03-13 | 2006-11-16 | Novo Nordisk A/S | Novel NPH insulin preparations |
US20050054818A1 (en) * | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
ES2328579T3 (es) * | 2003-07-25 | 2009-11-16 | Conjuchem Biotechnologies Inc. | Derivados de insulina de larga duracion y procedimientos asociados. |
EP2264065B1 (fr) | 2003-08-05 | 2017-03-08 | Novo Nordisk A/S | Nouveaux derives de l'insuline |
ATE517119T1 (de) * | 2003-12-03 | 2011-08-15 | Novo Nordisk As | Einzelketteninsulin |
CN101027318B (zh) | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
US8263551B2 (en) | 2004-11-22 | 2012-09-11 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
EP1679065A1 (fr) * | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Formulation destinée à la libération contrôlée d'interferone par un copolymère bloc PEGT/PBT |
EP1863840A1 (fr) * | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Insuline monocatenaire pegylee |
CN101389650B (zh) | 2005-12-28 | 2012-10-10 | 诺沃-诺迪斯克有限公司 | 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法 |
WO2007081824A2 (fr) * | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Protéines résistantes à la fibrillation |
US8927015B2 (en) * | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
EP2023947A4 (fr) * | 2006-05-10 | 2009-11-25 | Smithkline Beecham Corp | Composition et méthode améliorant la perméabilité cellulaire d'un composé |
WO2007135118A1 (fr) * | 2006-05-24 | 2007-11-29 | Novo Nordisk A/S | Formules solubles stables contenant de l'insuline |
EP2049149B1 (fr) | 2006-07-31 | 2015-04-15 | Novo Nordisk A/S | Insulines pegylées à extensions |
JP5864834B2 (ja) | 2006-09-22 | 2016-02-17 | ノボ・ノルデイスク・エー/エス | プロテアーゼ耐性のインスリンアナログ |
EP2074140B8 (fr) * | 2006-10-04 | 2015-10-28 | Case Western Reserve University | Insuline et analogues de l'insuline résistants à la fibrillation |
US9387176B2 (en) | 2007-04-30 | 2016-07-12 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
JP5552046B2 (ja) | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー/エス | インスリン誘導体を含有する薬学的製剤 |
KR20100053561A (ko) * | 2007-08-15 | 2010-05-20 | 노보 노르디스크 에이/에스 | 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체 |
WO2009050738A2 (fr) | 2007-10-16 | 2009-04-23 | Biocon Limited | Composition pharmaceutique solide administrable par voie orale et procédé associé |
DE102008003566A1 (de) * | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
BRPI0907119A2 (pt) | 2008-01-09 | 2015-07-14 | Sanofi Aventis Deutschland | Derivados de insulina tendo um perfil de ação de tempo extremamente retardado |
KR20100111682A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
JP5762001B2 (ja) | 2008-03-14 | 2015-08-12 | ノボ・ノルデイスク・エー/エス | プロテアーゼ安定化インスリンアナログ |
PT2254906T (pt) | 2008-03-18 | 2017-01-03 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
US8993516B2 (en) * | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
CN102065885A (zh) * | 2008-04-22 | 2011-05-18 | 卡斯西部储备大学 | 同种型特异性的胰岛素类似物 |
US9200053B2 (en) | 2008-07-31 | 2015-12-01 | Case Western Reserve University | Insulin analogues containing penta-fluoro-Phenylalanine at position B24 |
KR20120129875A (ko) * | 2008-07-31 | 2012-11-28 | 케이스 웨스턴 리저브 유니버시티 | 염소화 아미노산을 갖는 인슐린 유사체 |
KR101820024B1 (ko) | 2008-10-17 | 2018-01-18 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 glp-1 효능제의 병용물 |
US9603904B2 (en) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
AU2010208305A1 (en) | 2009-01-28 | 2011-09-08 | Smartcells, Inc. | Synthetic conjugates and uses thereof |
US9050370B2 (en) | 2009-01-28 | 2015-06-09 | Smartcells, Inc. | Conjugate based systems for controlled drug delivery |
US20100198188A1 (en) * | 2009-02-05 | 2010-08-05 | Abbott Diabetes Care Inc. | Devices and Methods for Metering Insoluble Active Agent Particles |
CA2754950A1 (fr) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Conjugues fonctionnalises aux extremites et leurs utilisations |
US20120241356A1 (en) * | 2009-07-06 | 2012-09-27 | Sanofi-Aventis Deutschland Gmbh | Heat- and vibration-stable insulin preparations |
US20120232002A1 (en) * | 2009-07-06 | 2012-09-13 | Sanofi-Aventis Deutschland Gmbh | Slow-acting insulin preparations |
US8399407B2 (en) * | 2009-09-17 | 2013-03-19 | Case Western Reserve University | Non-standard insulin analogues |
HUE037735T2 (hu) | 2009-11-13 | 2018-09-28 | Sanofi Aventis Deutschland | DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény |
ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
EP2504019A2 (fr) | 2009-11-25 | 2012-10-03 | ArisGen SA | Composition à libération par voie muqueuse contenant un peptide, un agent de couronne et/ou un contre-ion |
BR112012014025A2 (pt) | 2009-12-11 | 2017-01-31 | Univ Case Western Reserve | análogo de insulina, ácido nucleico, vetor de expressão, célula hospedeira e método de tratar um paciente |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
KR20130036290A (ko) | 2010-06-23 | 2013-04-11 | 노보 노르디스크 에이/에스 | 추가 이황화 결합을 함유하는 인슐린 유도체 |
BR112013004756B1 (pt) | 2010-08-30 | 2020-04-28 | Sanofi Aventis Deutschland | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 |
RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
WO2012171994A1 (fr) | 2011-06-15 | 2012-12-20 | Novo Nordisk A/S | Insulines à substitutions multiples |
RU2650616C2 (ru) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
CA2870313A1 (fr) | 2012-04-11 | 2013-10-17 | Novo Nordisk A/S | Formulations a base d'insuline |
JP6735561B2 (ja) | 2012-12-03 | 2020-08-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | O−グリコシル化カルボキシ末端部分(ctp)ペプチド系のインスリンおよびインスリン類似体 |
TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
DK2983697T3 (en) | 2013-04-03 | 2019-02-25 | Sanofi Sa | TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN |
EP2991672A1 (fr) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Schéma d'administration d'un nouveau type |
AU2014333979B2 (en) | 2013-10-07 | 2018-02-15 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
US9839692B2 (en) | 2014-01-09 | 2017-12-12 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
US9895424B2 (en) | 2014-01-09 | 2018-02-20 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
SG11201604706TA (en) * | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
CA2957714A1 (fr) * | 2014-08-11 | 2016-02-18 | Albany Medical College | Peptides apparentes a la leptine myristoylee et leurs utilisations |
US10392429B2 (en) | 2014-10-06 | 2019-08-27 | Case Western Reserve University | Biphasic single-chain insulin analogues |
JP6970615B2 (ja) | 2014-12-12 | 2021-11-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン/リキシセナチド固定比処方 |
CN105884879A (zh) * | 2015-01-26 | 2016-08-24 | 漳州博欣生物技术有限公司 | 一种胰岛素类似物的化学合成方法 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
EP3341403B1 (fr) * | 2015-08-25 | 2022-01-05 | Novo Nordisk A/S | Nouveaux dérivés d'insuline et utilisations médicales de ceux-ci |
CN105597087B (zh) * | 2016-01-06 | 2019-04-26 | 山东新时代药业有限公司 | 一种甘精胰岛素注射液及其制备方法 |
US11230585B2 (en) | 2016-09-06 | 2022-01-25 | Chemical & Biopharmaceutical Laboratories Of Patra | Proinsulin derivatives |
EP3329930A1 (fr) | 2016-12-05 | 2018-06-06 | Nuritas Limited | Compositions pharmaceutiques |
EP3548058B1 (fr) | 2016-12-05 | 2022-06-22 | Nuritas Limited | Compositions comprenant le peptide wkdeagkplvk |
CN110087674B (zh) | 2016-12-16 | 2023-01-03 | 诺和诺德股份有限公司 | 含胰岛素的药物组合物 |
US20200147215A1 (en) * | 2017-04-24 | 2020-05-14 | Simon H. Friedman | Drug conjugates with photocleavable solubility modulators |
JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
EP3727424A4 (fr) | 2017-12-18 | 2021-10-27 | Merck Sharp & Dohme Corp. | Systèmes à base de conjugués pour l'administration contrôlée d'insuline |
WO2019125879A2 (fr) | 2017-12-18 | 2019-06-27 | Merck Sharp & Dohme Corp. | Systèmes à base de conjugués pour l'administration contrôlée d'insuline |
CN112512534A (zh) * | 2018-05-14 | 2021-03-16 | 艾伊拉米治疗有限公司 | 用于回溶为高浓度液态溶液的胰岛素制剂 |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
MX2021006972A (es) | 2018-12-11 | 2021-08-16 | Sanofi Sa | Conjugados de insulina. |
CN110063932A (zh) * | 2019-04-12 | 2019-07-30 | 浙江大学 | 一种多肽蛋白类药物的缓释组合物制剂及其制备方法 |
TWI773009B (zh) | 2019-12-11 | 2022-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 新穎之胰島素類似物及其用途 |
CA3173417A1 (fr) | 2020-03-31 | 2021-10-07 | Alborz Mahdavi | Conjugues pour une reactivite selective a des diols vicinaux |
JP7456007B2 (ja) | 2020-05-15 | 2024-03-26 | イーライ リリー アンド カンパニー | 長時間作用アシル化インスリン化合物 |
EP4247429A1 (fr) | 2020-11-19 | 2023-09-27 | Protomer Technologies Inc. | Composés aromatiques contenant du bore et analogues d'insuline |
WO2022125587A1 (fr) * | 2020-12-07 | 2022-06-16 | Case Western Reserve University | Analogues acylés de l'insuline à chaîne unique |
TW202409070A (zh) | 2022-05-18 | 2024-03-01 | 美商普羅托莫科技公司 | 芳族含硼化合物及相關胰島素類似物 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2538018A (en) | 1944-04-04 | 1951-01-16 | Nordisk Insulinlab | Crystalline product of insulin and alkaline protein and process of making it |
US2801953A (en) | 1952-02-28 | 1957-08-06 | Hoechst Ag | Process of preparing crystallized insulin preparations |
US2849370A (en) | 1953-06-04 | 1958-08-26 | Novo Terapeutisk Labortorium A | Injectable insulin preparations with protracted effect and process of producing same |
US3102077A (en) | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
US3060093A (en) | 1957-07-18 | 1962-10-23 | Nordisk Insulinlab | Slowly acting insulin preparation in crystalline form and method of preparation |
DE1793517C3 (de) | 1968-09-28 | 1974-12-05 | Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt | N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung |
US3869437A (en) | 1970-05-08 | 1975-03-04 | Nat Res Dev | Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin |
US3950517A (en) | 1970-05-08 | 1976-04-13 | National Research Development Corporation | Insulin derivatives |
GB1381274A (en) | 1971-01-28 | 1975-01-22 | Nat Res Dev | Insulin derivatives |
US3868358A (en) | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
US3865325A (en) | 1971-07-02 | 1975-02-11 | Dylaker Computer Systems Inc | Flexible tape reel |
US3907763A (en) | 1972-03-01 | 1975-09-23 | Bayer Ag | Insulin derivatives crosslinked by a dicarboxylic acid moiety |
US4183849A (en) | 1975-01-15 | 1980-01-15 | Nordisk Insulinlaboratorium | Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect |
JPS55138391A (en) | 1979-04-13 | 1980-10-29 | Shionogi & Co Ltd | New synthetic method of peptide derivative |
JPS55138393A (en) | 1979-04-13 | 1980-10-29 | Shionogi & Co Ltd | Semisynthesis of insulin |
IE50892B1 (en) | 1980-02-11 | 1986-08-06 | Novo Industri As | Process for preparing insulin esters |
DE3101382A1 (de) | 1981-01-17 | 1982-09-02 | Hoechst Ag, 6000 Frankfurt | "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten" |
DK353781A (da) | 1981-08-10 | 1983-02-11 | Novo Industri As | Fremgangsmaade til fremstilling af insulinderivater |
JPS58501455A (ja) | 1981-09-15 | 1983-09-01 | ノルデイスク インシユリンラボラトリユ−ム | 人インシユリンまたはそのb−30エステルの製造法 |
DE3326473A1 (de) | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
DE3327709A1 (de) | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
US4946828A (en) * | 1985-03-12 | 1990-08-07 | Novo Nordisk A/S | Novel insulin peptides |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
WO1990001038A1 (fr) | 1988-07-20 | 1990-02-08 | Nordisk Gentofte A/S | Analogues d'insuline humaine et preparations les contenant |
DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
AU641631B2 (en) | 1988-12-23 | 1993-09-30 | Novo Nordisk A/S | Human insulin analogues |
NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
DK134189D0 (da) | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
DE122006000017I1 (de) | 1993-06-21 | 2006-06-29 | Novo Nordisk As | ASP-B28-Insulinkristalle |
DK72793D0 (da) * | 1993-06-21 | 1993-06-21 | Novo Nordisk As | Nyt produkt |
WO1995007931A1 (fr) * | 1993-09-17 | 1995-03-23 | Novo Nordisk A/S | Insuline acylee |
US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5597893A (en) | 1994-10-31 | 1997-01-28 | Eli Lilly And Company | Preparation of stable insulin analog crystals |
US5646242A (en) * | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
US5693609A (en) * | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
CN1196061A (zh) | 1995-03-17 | 1998-10-14 | 诺沃挪第克公司 | 胰岛素衍生物 |
US5700904A (en) * | 1995-06-07 | 1997-12-23 | Eli Lilly And Company | Preparation of an acylated protein powder |
US5877153A (en) | 1996-06-11 | 1999-03-02 | Commonwealth Biotechnologies Inc. | Heparin-binding peptides |
ATE369146T1 (de) | 1996-06-20 | 2007-08-15 | Novo Nordisk As | Insulinpreparation mit mannitol |
US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
ES2242270T3 (es) | 1997-02-07 | 2005-11-01 | Novo Nordisk A/S | Cristalizacion de proteinas. |
ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
-
1998
- 1998-10-22 JP JP2000517736A patent/JP2001521006A/ja not_active Withdrawn
- 1998-10-22 ID IDW20000748A patent/ID24890A/id unknown
- 1998-10-22 WO PCT/US1998/022313 patent/WO1999021573A1/fr not_active Application Discontinuation
- 1998-10-22 CN CN98810334A patent/CN1276731A/zh active Pending
- 1998-10-22 CO CO98061475A patent/CO4970769A1/es unknown
- 1998-10-22 BR BR9813111-7A patent/BR9813111A/pt not_active IP Right Cessation
- 1998-10-22 AU AU11117/99A patent/AU1111799A/en not_active Abandoned
- 1998-10-22 CA CA002306905A patent/CA2306905A1/fr not_active Abandoned
- 1998-10-22 HU HU0004169A patent/HUP0004169A3/hu unknown
- 1998-10-22 KR KR1020007004395A patent/KR20010024556A/ko not_active Application Discontinuation
- 1998-10-22 US US09/177,685 patent/US6268335B1/en not_active Expired - Lifetime
- 1998-10-22 JP JP2000517731A patent/JP2001521004A/ja not_active Withdrawn
- 1998-10-22 IL IL13490198A patent/IL134901A0/xx unknown
- 1998-10-22 CA CA002306877A patent/CA2306877A1/fr not_active Abandoned
- 1998-10-22 TR TR2000/01050T patent/TR200001050T2/xx unknown
- 1998-10-22 AR ARP980105267A patent/AR020047A1/es unknown
- 1998-10-22 WO PCT/US1998/022434 patent/WO1999021578A1/fr not_active Application Discontinuation
- 1998-10-22 PL PL98340255A patent/PL340255A1/xx not_active Application Discontinuation
- 1998-10-22 SV SV1998000125A patent/SV1998000125A/es unknown
- 1998-10-22 AU AU11166/99A patent/AU747926B2/en not_active Ceased
- 1998-10-22 EP EP98953852A patent/EP1039920A4/fr not_active Withdrawn
- 1998-10-22 PE PE1998000996A patent/PE123799A1/es not_active Application Discontinuation
- 1998-10-22 EA EA200000453A patent/EA200000453A1/ru unknown
-
2000
- 2000-04-18 NO NO20002038A patent/NO20002038L/no not_active Application Discontinuation
- 2000-04-21 HR HR20000236A patent/HRP20000236A2/hr not_active Application Discontinuation
-
2001
- 2001-01-17 US US09/761,903 patent/US6465426B2/en not_active Expired - Fee Related
- 2001-12-06 US US10/010,038 patent/US20020082199A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HRP20000236A2 (en) | 2001-02-28 |
ID24890A (id) | 2000-08-31 |
PE123799A1 (es) | 1999-12-13 |
US20020082199A1 (en) | 2002-06-27 |
JP2001521006A (ja) | 2001-11-06 |
PL340255A1 (en) | 2001-01-29 |
AU747926B2 (en) | 2002-05-30 |
WO1999021578A1 (fr) | 1999-05-06 |
BR9813111A (pt) | 2000-08-15 |
AR020047A1 (es) | 2002-04-10 |
CN1276731A (zh) | 2000-12-13 |
AU1116699A (en) | 1999-05-17 |
HUP0004169A2 (hu) | 2001-05-28 |
JP2001521004A (ja) | 2001-11-06 |
US20010036916A1 (en) | 2001-11-01 |
EA200000453A1 (ru) | 2000-10-30 |
KR20010024556A (ko) | 2001-03-26 |
AU1111799A (en) | 1999-05-17 |
EP1039920A4 (fr) | 2003-05-28 |
CA2306905A1 (fr) | 1999-05-06 |
US6465426B2 (en) | 2002-10-15 |
NO20002038L (no) | 2000-06-26 |
WO1999021573A1 (fr) | 1999-05-06 |
NO20002038D0 (no) | 2000-04-18 |
IL134901A0 (en) | 2001-05-20 |
SV1998000125A (es) | 1999-05-24 |
HUP0004169A3 (en) | 2001-06-28 |
TR200001050T2 (tr) | 2000-08-21 |
CO4970769A1 (es) | 2000-11-07 |
EP1039920A1 (fr) | 2000-10-04 |
US6268335B1 (en) | 2001-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6465426B2 (en) | Insoluble insulin compositions | |
EP0925792B1 (fr) | Compositions insolubles d'insuline pour le contrôle du glucose sanguin | |
US20050176621A1 (en) | Crystalline compositions for controlling blood glucose | |
EP0712861B1 (fr) | Analogues d'insuline acylés | |
US5547929A (en) | Insulin analog formulations | |
JP2002543092A (ja) | 肺投与用インスリン結晶 | |
CZ154395A3 (en) | Insulin analogous protamine complex, process of its preparation and parenteral pharmaceutical composition containing thereof | |
US20050054818A1 (en) | Crystalline compositions for controlling blood glucose | |
DeFelippis et al. | Insulin self-association and the relationship to pharmacokinetics and pharmacodynamics | |
EP0969860B1 (fr) | Procede de preparation d'une poudre therapeutique par co-precipitation d'insuline et d'un activateur de l'absorption | |
EP0911035A2 (fr) | Compositions non solubles d' insuline | |
EP1396272A1 (fr) | Compositions insolubles d'insuline pour le contrôle du glucose sanguin | |
MXPA00003955A (en) | Insoluble insulin compositions | |
WO2001000675A1 (fr) | Compositions insuliniques acylees insolubles exemptes de protamine | |
CZ20002339A3 (cs) | Nerozpustné kompozice pro ovlivňování glukózy v krvi | |
CZ20001492A3 (cs) | Přípravky nerozpustného inzulínu | |
MXPA00006209A (en) | Insoluble compositions for controlling blood glucose | |
AU734304B2 (en) | Acylated insulin analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |